These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1188 related items for PubMed ID: 30416083

  • 1. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
    Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, BORA study investigators.
    Lancet Respir Med; 2019 Jan; 7(1):46-59. PubMed ID: 30416083
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab.
    Bourdin A, Chupp G, Jackson DJ, Cohen D, Emerath U, Shavit A, Kurdyukova Y, Menzies-Gow A.
    J Allergy Clin Immunol Pract; 2024 Aug; 12(8):2074-2083.e4. PubMed ID: 38677588
    [Abstract] [Full Text] [Related]

  • 8. Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma.
    FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, Barker P, Martin UJ.
    J Asthma Allergy; 2019 Aug; 12():401-413. PubMed ID: 31849500
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years.
    Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG.
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4381-4392.e4. PubMed ID: 34487870
    [Abstract] [Full Text] [Related]

  • 12. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 14. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG.
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [Abstract] [Full Text] [Related]

  • 20. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
    Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R.
    Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.